Possible Role of Interleukin-31/33 Axis in Imatinib Mesylate-Associated Skin Toxicity

Imatinib mesylate is a small-molecule tyrosine kinase inhibitor (TKi) designed to target c-ABL and BCR-ABL, approved for the treatment of chronic myeloid leukemia and gastrointestinal stromal tumors. Adverse cutaneous reactions induced by imatinib are frequent, generally moderate, and dose-dependent...

Full description

Bibliographic Details

Published in:	Turkish Journal of Hematology
Main Authors:	Caterina Musolino, Alessandro Allegra, Carmen Mannucci, Sabina Russo, Andrea Alonci, Valerio Maisano, Gioacchino Calapai, Sebastiano Gangemi
Format:	Article
Language:	English
Published:	Turkish Society of Hematology 2015-05-01
Subjects:	interleukin-31 (il-31) interleukin-33 (il-33) tyrosine kinase inhibitors imatinib mesylate chronic myeloid leukemia pruritus
Online Access:	https://jag.journalagent.com/z4/download_fulltext.asp?pdir=tjh&un=TJH-76402